A growing, cash-generative drug franchise entering a debt-funded expansion phase
Across its multi-year history, Vertex paired expanding revenue with substantial operating cash generation and capital spending that was modest relative to cash flow. Its historically cash-rich, lightly indebted position supported research, launches, and shareholder returns, though special and acquisition-related costs can make reported earnings uneven.